TORONTO, Feb. 4, 2013 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a
conference call on Thursday, February 7th, 2013 at 4:30 P.M. EST to
discuss Second Quarter Fiscal 2013 financial results. Dr. Tony Cruz,
Chairman and Chief Executive Officer of the Company, will host the
call. Transition will announce its financial results for this period in
a press release to be issued prior to the call. In order to
participate in the conference call, please call 1-800-773-0519 (North
America), 1-212-231-2934 (International). A replay of the conference
call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.
Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead product
is ELND005 for the treatment of Alzheimer's disease and bipolar
disorder. Transition also has an emerging pipeline of innovative
preclinical and clinical drug candidates. The other drugs in the
pipeline that the Company is developing are for anti-inflammatory and
metabolic indications. Transition's shares are listed on the NASDAQ
under the symbol "TTHI" and the Toronto Stock Exchange under the symbol
"TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials and potential efficacy of its products.
These statements are based upon the current expectations and beliefs of
Transition's management and are subject to certain risks and
uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the risk
factors and other cautionary statements discussed in Transition's
quarterly and annual filings with the Canadian commissions.
SOURCE: Transition Therapeutics Inc.
For further information:
For further information on Transition, visit www.transitiontherapeutics.com or contact:
Dr. Tony Cruz
Chief Executive Officer
Transition Therapeutics Inc.
Phone: 416-260-7770, x.223